Benzinga · Aug 12, 2026
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
BC
NASDAQ · BCAX
Bicara Therapeutics Inc. Common Stock
Healthcare · Biotechnology
$24.39
Down-$0.49 (-2.01%)
Updated Aug 21, 2026, 11:23 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.03B
- P/E ratio
- -10.02
- Dividend yield
- 0.00%
- 52-week range
- $10.30 – $30.99
- Volume
- 448.99K
- Avg. volume
- 676.71K
Price performance
BCAX price history
1M range · 21 trading sessions · Daily adjusted prices
BCAX closed at $24.39 after 21 trading sessions, down 12.04% for the selected period.
- Last close
- $24.39
- Period change
- -12.04%
- Period low
- $23.63
- Period high
- $28.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $25.44 | $25.788 | $24.27 | $24.39 | 448.99K |
| Aug 19, 2026 | $26.09 | $26.95 | $25.04 | $25.86 | 670.44K |
| Aug 18, 2026 | $24.71 | $25.45 | $24.47 | $24.92 | 446.13K |
| Aug 17, 2026 | $24.28 | $25.00 | $24.1261 | $24.94 | 434.69K |
| Aug 14, 2026 | $23.51 | $24.9731 | $23.27 | $24.28 | 479.91K |
| Aug 13, 2026 | $24.89 | $24.93 | $23.33 | $23.63 | 751.52K |
| Aug 12, 2026 | $24.00 | $25.14 | $23.88 | $24.63 | 810.3K |
| Aug 11, 2026 | $22.80 | $26.915 | $22.80 | $23.76 | 1.72M |
| Aug 10, 2026 | $27.83 | $28.40 | $27.0676 | $27.73 | 949.33K |
| Aug 7, 2026 | $27.90 | $28.4299 | $26.90 | $28.06 | 570.57K |
| Aug 6, 2026 | $26.11 | $27.68 | $26.06 | $27.51 | 704.02K |
| Aug 5, 2026 | $26.31 | $26.62 | $25.34 | $25.89 | 818.32K |
| Aug 4, 2026 | $26.24 | $26.87 | $25.80 | $26.10 | 815.07K |
| Aug 3, 2026 | $26.85 | $26.85 | $25.70 | $25.74 | 398.98K |
| Jul 31, 2026 | $26.62 | $27.12 | $25.35 | $27.10 | 690.17K |
| Jul 30, 2026 | $26.00 | $26.89 | $25.84 | $26.27 | 826.58K |
| Jul 29, 2026 | $26.88 | $27.04 | $25.81 | $25.89 | 509.36K |
| Jul 28, 2026 | $27.62 | $28.90 | $26.46 | $26.88 | 489.92K |
| Jul 27, 2026 | $27.36 | $28.92 | $27.36 | $27.81 | 499.48K |
| Jul 24, 2026 | $27.73 | $28.22 | $26.685 | $27.02 | 481.66K |
| Jul 23, 2026 | $27.55 | $28.33 | $26.955 | $27.73 | 357.45K |
Latest BCAX news
The latest Smart Investors Daily articles mentioning BCAX.
Stock researchCompany · Overview
BCAX research
Overview
Company profile and research snapshot.
Company profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $40.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 12, 2026 | Morgan Stanley | Overweight | — |
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | Goldman Sachs | Neutral | — |
| Aug 12, 2026 | Mizuho | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.
Benzinga · Aug 12, 2026
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.
SeekingAlpha · Aug 12, 2026
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Bicara Therapeutics upgraded to Buy on early ficerafusp alfa data in head & neck cancer; review phase 1 results, cash runway & catalysts. Click for more on BCAX stock.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
